Harvard Bioscience, Inc. is a developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bioproduction and preclinical testing for pharmaceutical and therapy development. Its products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations (CROs). Its two product categories are cellular and molecular technology (CMT) and Preclinical. The CMT product family is primarily composed of products supporting research related to molecular, cellular, organ and organoid technologies. The Preclinical product family includes products that support the preclinical research and testing phase for drug development, and in particular, testing related to data collection and analysis for safety and regulatory compliance.
Símbolo de cotizaciónHBIO
Nombre de la empresaHarvard Bioscience Inc
Fecha de salida a bolsaOct 21, 2013
Director ejecutivoMr. John D. Duke
Número de empleados330
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 21
Dirección84 October Hill Rd
CiudadHOLLISTON
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal01746-1371
Teléfono15088938999
Sitio Webhttps://www.harvardbioscience.com/
Símbolo de cotizaciónHBIO
Fecha de salida a bolsaOct 21, 2013
Director ejecutivoMr. John D. Duke
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos